RonaldYap,MD CONCORD HOSPITAL CENTER FOR UROLOGIC CARE 36 Regional Presence Expansion *American Cancer Society. https://cancerstatisticscenter.cancer.org/#!/state/New%20Hampshire\ CENTER FOR UROLOGIC CARE From enlarged prostate to life-threatening cancer, chronic pelvic pain to excruciating kidney stones, experienced specialists at Concord Hospital Center for Urologic Care provide timely, effective and comprehensive care. Our physicians and providers work as a team, building on each other’s skills to ensure that patients are supported from diagnosis to treatment and beyond, as they and their families adapt to the sometimes lifelong effects of their conditions. FusionBiopsy In 2017, Concord Hospital Center for Urologic Care became the first in New Hampshire to begin using a new technique that more accurately diagnoses prostate cancer, saving lives and preventing patients from undergoing unnecessary prostate biopsies. Prostate cancer is the most commonly diagnosed cancer among men and the second leading cause of cancer death among men in New Hampshire*. Each year, the Center for Urologic Care conducts an average of 300 prostate biopsies. In 2016, less than half, 132 discovered prostate cancer. Urologists recognize that the traditional diagnosis method exposes too many men to needless biopsies and often misses small cancers. The new technology, Fusion Biopsy, fuses, or matches, ultrasound imaging and Magnetic Resonance Imaging (MRI) to provide a vivid‘live’view of potential tumors, enabling doctors to precisely target biopsies – increasing the rate of finding significant cancers by 30 percent. At Center for Urologic Care, Dr.William Santis said traditionally, a biopsy might be ordered to obtain tiny prostate tissue samples from men with abnormal prostate exams or elevated PSA blood levels. Prostate-specific antigen, or PSA, levels often are elevated in men with prostate cancer, but also can be elevated for other, non-cancerous reasons. For a traditional biopsy, doctors guided by ultrasound images obtain samples from different regions of the prostate, with no specific targets. For patients whose test results suggest an MRI, targets are identified by MRI images, which doctors study before using ultrasound images to guide a probe to those general areas. The major advance is fusing previously obtained MRI images with live ultrasound imaging to guide the biopsy needle to very specific targets.The MRI images essentially come alive and match the movements of the ultrasound device. Dr. Santis said because they are more useful than traditional ultrasound-guided, regional, but untargeted biopsies, MRIs that can precisely identify potential tumors soon may become the standard for men with elevated PSA levels.The routine use of MRI and other blood tests to follow up elevated PSA levels also may allow up to 20 percent of men with an elevated PSA to avoid biopsies. For men who need a biopsy to confirm or rule out cancer, he believes the bulk of biopsies soon may be performed with the fusion technique. Concord Hospital Center for Urologic Care performs approximately 30-40 prostate MRIs per month. Between July and October, 2017, Dr. Santis and colleague Dr. Amichai Kilchevsky performed approximately 40 fusion biopsies. RonaldYap,MD CONCORD HOSPITAL CENTER FOR UROLOGIC CARE We collaboratetocareforpatients.